

NHS Gynaecology Collaborative

Female Urinary Incontinence (UI) Pathway

Red Flags:

Dysuria & unexplained non- visible haematuria >60yo Bladder Cancer

Haematuria (visible or non-visible) with Dysuria or ↑wcc on FBC, **Bladder Cancer**

Haematuria (visible) with ↓ Hb/ ↑platelets/↑ glucose Or unexplained vaginal discharge **Endometrial Cancer**

Unexplained & Recurrent or Persistent UTI >60vo **Bladder Cancer**

Urgency +/- Frequency increasing, persistent or frequent, >12x per month in >50yo Ovarian Cancer

Urinary Retention or Palpable

Refer to Urology on call: Bladder

Lifestyle Advice:

Smoking Cessation Modify Fluid intake in evenings (if nocturia) **Reduce Caffeinated Drinks** Weight Loss **Avoid Constipation**

Assessment:

Symptoms Obstetric History Constipation & Faecal Incontinence Medication (eg diuretics) Caffeine Intake Pad Usage Impact on Quality of Life Medical History-Chronic Respiratory Disease, Neurological Conditions, Pelvic Radiotherapy/Surgery **Bladder Diary** Check Prolapse & Pelvic Floor Tone



Determine type of Incontinence

Urinalysis & MSU; Treat UTI

Stress Urinary Incontinence (SUI) Overactive Bladder (OAB) or Urge Incontinence Mixed Urinary Incontinence

Patient Resources:

Bladder Training Bladder & Bowel Service Patient Website

Refer Gynaecology Collaborative: (For Secondary Care Referral)


Persistent Bladder/Urethral Pain **Symptoms of Voiding Difficulties** Symptomatic Prolapse considering surgery **Previous Continence Surgery** Suspected Urogenital Fistula Previous Pelvic Radiotherapy/Cancer Surgery Suspected Neurological Disease **Associated Faecal Incontinence** Benign Pelvic Mass

Based on most recent published guidance & local medicines management policies In collaboration with local consultant gynaecologists



All Gynaecological referrals (except 2 week-wait referrals) will be processed by The Gynaecology Collaborative

Female Urinary Incontinence (UI) Pathway



Release Tablets for OAB or Mixed UI
Oxybutinin Patches if unable to tolerate oral
Avoid Oxybutinin in frail elderly women >75yo
Solifenacin
Mirabegron restricted to failed treatment with 2 agents
each tried for 4 weeks or antimuscarinics contraindicated
Review dose & adjust as tolerated after 4 weeks use
Review tolerability, adherence, efficacy
Annual review or every 6m if >75yo

Please consider further guidance https://cks.nice.org.uk/incontinence-urinary-in-women#!management

Created July 2020, Review 2025 Dr Belinda Solomon

Drug Holiday 4 weeks, discontinue if successful

Based on most recent published guidance & local medicines management policies In collaboration with local consultant gynaecologists